Dr. Neville Wilson. – 04.02.08
The long awaited results, of what has become a controversial drug trial, were announced recently.
Controversies arising in the wake of a disappointing outcome for the ENHANCE TRIAL have provoked challenging commentaries from critical observers, and also defensive responses from the research team, seeking to minimise the impact of the trial’s shortcomings.
Numerous concerns have been expressed, arising from anomalies within the trial.
The failure of Ezetimibe, an adjunctive cholesterol lowering agent , to produce a favourable result in this trial, has inescapable implications for prescribing doctors, for the drug manufacturer, and for the countless numbers of patients for whom LDL-C lowering drugs have been prescribed.
Click to read the full article on: The Enhance Trial by Dr Neville Wilson